Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 12.78 USD 4.07% Market Closed
Market Cap: 691.7m USD

Wall Street
Price Targets

FULC Price Targets Summary
Fulcrum Therapeutics Inc

Wall Street analysts forecast FULC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FULC is 19.38 USD with a low forecast of 7.07 USD and a high forecast of 26.25 USD.

Lowest
Price Target
7.07 USD
45% Downside
Average
Price Target
19.38 USD
52% Upside
Highest
Price Target
26.25 USD
105% Upside
Fulcrum Therapeutics Inc Competitors:
Price Targets
6996
Antengene Corporation Ltd
83% Upside
234080
JW Life Science Corp
32% Upside
1760
Panion & BF Biotech Inc
30% Upside
IOLCP
IOL Chemicals and Pharmaceuticals Ltd
34% Upside
1093
CSPC Pharmaceutical Group Ltd
15% Upside
CONCORDBIO
Concord Biotech Ltd
27% Upside

Revenue
Forecast

Revenue Estimate
Fulcrum Therapeutics Inc

The compound annual growth rate of Fulcrum Therapeutics Inc's revenue for the next 4 years is -29%.

N/A
Past Growth
-29%
Estimated Growth
Estimates Accuracy
19%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Fulcrum Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
Fulcrum Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FULC's stock price target?
Price Target
19.38 USD

According to Wall Street analysts, the average 1-year price target for FULC is 19.38 USD with a low forecast of 7.07 USD and a high forecast of 26.25 USD.

What is Fulcrum Therapeutics Inc's Revenue forecast?
Projected CAGR
-29%

The compound annual growth rate of Fulcrum Therapeutics Inc's revenue for the next 4 years is -29%.

Back to Top